<?xml version='1.0' encoding='utf-8'?>
<document id="27070564"><sentence text="In Vivo and in Vitro Study on Drug-Drug Interaction of Lovastatin and Berberine from Pharmacokinetic and HepG2 Cell Metabolism Studies."><entity charOffset="55-65" id="DDI-PubMed.27070564.s1.e0" text="Lovastatin" /><entity charOffset="70-79" id="DDI-PubMed.27070564.s1.e1" text="Berberine" /><pair ddi="false" e1="DDI-PubMed.27070564.s1.e0" e2="DDI-PubMed.27070564.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27070564.s1.e0" e2="DDI-PubMed.27070564.s1.e1" /></sentence><sentence text="We assumed that the pharmacokinetics of lovastatin could be changed by the induction effect of berberine"><entity charOffset="40-50" id="DDI-PubMed.27070564.s2.e0" text="lovastatin" /><entity charOffset="95-104" id="DDI-PubMed.27070564.s2.e1" text="berberine" /><pair ddi="false" e1="DDI-PubMed.27070564.s2.e0" e2="DDI-PubMed.27070564.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27070564.s2.e0" e2="DDI-PubMed.27070564.s2.e1" /></sentence><sentence text="" /><sentence text="An UPLC-MS/MS method was developed and validated for the pharmacokinetics tudy of lovastatin to investigate the in vivo drug-drug interactions between lovastatin and berberine"><entity charOffset="82-92" id="DDI-PubMed.27070564.s4.e0" text="lovastatin" /><entity charOffset="151-161" id="DDI-PubMed.27070564.s4.e1" text="lovastatin" /><entity charOffset="166-175" id="DDI-PubMed.27070564.s4.e2" text="berberine" /><pair ddi="false" e1="DDI-PubMed.27070564.s4.e0" e2="DDI-PubMed.27070564.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27070564.s4.e0" e2="DDI-PubMed.27070564.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27070564.s4.e0" e2="DDI-PubMed.27070564.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27070564.s4.e1" e2="DDI-PubMed.27070564.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27070564.s4.e1" e2="DDI-PubMed.27070564.s4.e2" /></sentence><sentence text=" SD male rats were random divided into lovastatin group and berberine induced prior to lovastatin group for the in vivo pharmacokinetic studies"><entity charOffset="39-49" id="DDI-PubMed.27070564.s5.e0" text="lovastatin" /><entity charOffset="60-69" id="DDI-PubMed.27070564.s5.e1" text="berberine" /><entity charOffset="87-97" id="DDI-PubMed.27070564.s5.e2" text="lovastatin" /><pair ddi="false" e1="DDI-PubMed.27070564.s5.e0" e2="DDI-PubMed.27070564.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27070564.s5.e0" e2="DDI-PubMed.27070564.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27070564.s5.e0" e2="DDI-PubMed.27070564.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27070564.s5.e1" e2="DDI-PubMed.27070564.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27070564.s5.e1" e2="DDI-PubMed.27070564.s5.e2" /></sentence><sentence text=" Meanwhile HepG2 cells were induced by berberine for three days to study the metabolism of lovastatin"><entity charOffset="39-48" id="DDI-PubMed.27070564.s6.e0" text="berberine" /><entity charOffset="91-101" id="DDI-PubMed.27070564.s6.e1" text="lovastatin" /><pair ddi="false" e1="DDI-PubMed.27070564.s6.e0" e2="DDI-PubMed.27070564.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27070564.s6.e0" e2="DDI-PubMed.27070564.s6.e1" /></sentence><sentence text="" /><sentence text="The AUC (p &lt; 0" /><sentence text="01) and Cmax (p &lt; 0" /><sentence text="01) could be significantly decreased in the berberine-induced group in vivo, and the metabolic activity of HepG2 cell ccould be increased by berberine induction in vitro"><entity charOffset="44-53" id="DDI-PubMed.27070564.s10.e0" text="berberine" /><entity charOffset="141-150" id="DDI-PubMed.27070564.s10.e1" text="berberine" /><pair ddi="false" e1="DDI-PubMed.27070564.s10.e0" e2="DDI-PubMed.27070564.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27070564.s10.e0" e2="DDI-PubMed.27070564.s10.e1" /></sentence><sentence text=" The metabolism parameters of lovastatin such as CL, Vmax and Km were increased after the induction of berberine"><entity charOffset="30-40" id="DDI-PubMed.27070564.s11.e0" text="lovastatin" /><entity charOffset="103-112" id="DDI-PubMed.27070564.s11.e1" text="berberine" /><pair ddi="false" e1="DDI-PubMed.27070564.s11.e0" e2="DDI-PubMed.27070564.s11.e0" /><pair ddi="false" e1="DDI-PubMed.27070564.s11.e0" e2="DDI-PubMed.27070564.s11.e1" /></sentence><sentence text=" From the pharmacokinetic study of lovastatin induced with berberine, we obtained pharmacokinetic parameters which are compliance with the metabolic parameters of lovastatin in HepG2 cells with berberine induction in vitro"><entity charOffset="35-45" id="DDI-PubMed.27070564.s12.e0" text="lovastatin" /><entity charOffset="59-68" id="DDI-PubMed.27070564.s12.e1" text="berberine" /><entity charOffset="163-173" id="DDI-PubMed.27070564.s12.e2" text="lovastatin" /><entity charOffset="194-203" id="DDI-PubMed.27070564.s12.e3" text="berberine" /><pair ddi="false" e1="DDI-PubMed.27070564.s12.e0" e2="DDI-PubMed.27070564.s12.e0" /><pair ddi="false" e1="DDI-PubMed.27070564.s12.e0" e2="DDI-PubMed.27070564.s12.e1" /><pair ddi="false" e1="DDI-PubMed.27070564.s12.e0" e2="DDI-PubMed.27070564.s12.e2" /><pair ddi="false" e1="DDI-PubMed.27070564.s12.e0" e2="DDI-PubMed.27070564.s12.e3" /><pair ddi="false" e1="DDI-PubMed.27070564.s12.e1" e2="DDI-PubMed.27070564.s12.e1" /><pair ddi="false" e1="DDI-PubMed.27070564.s12.e1" e2="DDI-PubMed.27070564.s12.e2" /><pair ddi="false" e1="DDI-PubMed.27070564.s12.e1" e2="DDI-PubMed.27070564.s12.e3" /><pair ddi="false" e1="DDI-PubMed.27070564.s12.e2" e2="DDI-PubMed.27070564.s12.e2" /><pair ddi="false" e1="DDI-PubMed.27070564.s12.e2" e2="DDI-PubMed.27070564.s12.e3" /></sentence><sentence text="" /><sentence text="From the in vivo pharmacokinetics study and the HepG2 cell metabolism study in vitro, berberine could be an inducer for the metabolism of lovastatin according to our previous research on berberine induction effects on HepG2 cells, which may be relevant to the fact that berberine possesses induction effects through the CYP 450 3A4 enzyme"><entity charOffset="86-95" id="DDI-PubMed.27070564.s14.e0" text="berberine" /><entity charOffset="138-148" id="DDI-PubMed.27070564.s14.e1" text="lovastatin" /><entity charOffset="187-196" id="DDI-PubMed.27070564.s14.e2" text="berberine" /><entity charOffset="270-279" id="DDI-PubMed.27070564.s14.e3" text="berberine" /><pair ddi="false" e1="DDI-PubMed.27070564.s14.e0" e2="DDI-PubMed.27070564.s14.e0" /><pair ddi="false" e1="DDI-PubMed.27070564.s14.e0" e2="DDI-PubMed.27070564.s14.e1" /><pair ddi="false" e1="DDI-PubMed.27070564.s14.e0" e2="DDI-PubMed.27070564.s14.e2" /><pair ddi="false" e1="DDI-PubMed.27070564.s14.e0" e2="DDI-PubMed.27070564.s14.e3" /><pair ddi="false" e1="DDI-PubMed.27070564.s14.e1" e2="DDI-PubMed.27070564.s14.e1" /><pair ddi="false" e1="DDI-PubMed.27070564.s14.e1" e2="DDI-PubMed.27070564.s14.e2" /><pair ddi="false" e1="DDI-PubMed.27070564.s14.e1" e2="DDI-PubMed.27070564.s14.e3" /><pair ddi="false" e1="DDI-PubMed.27070564.s14.e2" e2="DDI-PubMed.27070564.s14.e2" /><pair ddi="false" e1="DDI-PubMed.27070564.s14.e2" e2="DDI-PubMed.27070564.s14.e3" /></sentence><sentence text="" /></document>